Palivizumab
Synagis (palivizumab) is an antibody pharmaceutical. Palivizumab was first approved as Synagis on 1998-06-19. It is used to treat respiratory syncytial virus infections in the USA. It has been approved in Europe to treat respiratory syncytial virus infections.
| Trade Name | Synagis |
|---|---|
| Common Name | Palivizumab |
| Indication | respiratory syncytial virus infections |
| Drug Class | Monoclonal antibodies: humanized, antiviral indications |
